What are the red flags for Chris DeRienzo, MD?

Chris DeRienzo, MD

SVP & Chief Physician Executive

Senior Vice President and Chief Physician Executive, AHA; President, Health Research & Educational Trust | American Hospital Association

Last verified November 4, 2026

5 Red Flags

Affiliations

•Senior Vice President and Chief Physician Executive of the AHA since his appointment in December 2022, and President of the Health Research & Educational Trust (HRET); he remains on the Executive Management Group under CEO Steve Walsh as of November 2026.
•Former System Chief Medical Officer and SVP of Quality at WakeMed Health & Hospitals in Raleigh, N.C., his role immediately before AHA.
•Former Chief Quality Officer at Mission Health in Asheville, N.C.
•Independent director on the board of Mednition, a clinical AI company selling to hospitals, since March 2024; Mednition is a portfolio company of the AHA Innovation Fund via Concord Health Partners.
•Listed as an adviser to Concord Health Partners, the investment firm that manages the AHA Innovation Development Fund, and as Chief Medical Officer of Prealize Health, an AI predictive analytics company.
•Former member of Premier Inc.'s board of advisors (through 2022).
•MD from Duke University and MPP from Duke's Sanford School; board-certified in pediatrics and neonatology.

Financial / Compensation

•DeRienzo's reportable 2024 compensation was $886,847 plus $174,720 in other compensation, about $1.06 million total, per AHA's 2024 Form 990.
•His reportable pay was $829,789 in 2023, per Paddock Post.
•The 2024 Form 990 shows him working about one hour a week for related organizations with no related-organization pay reported.
•Compensation, if any, from his Mednition board seat or Concord Health Partners advisory role is not publicly disclosed.
•AHA's 2024 Form 990 reports total revenue of $146.7 million against expenses of $169.3 million, a $22.6 million operating deficit, with net assets falling from $289.8 million to $277.6 million during the year.
•Former CEO Rick Pollack's reportable 2024 compensation was $5,823,759 (plus $55,174 other compensation), up from $3,396,123 in 2023.

Lobbying and Political

•DeRienzo is not a registered federal lobbyist on AHA's 2025 or 2026 LDA reports.
•AHA's in-house LDA reports show $25.47 million in federal lobbying for 2025 (Q1 $7.03M, Q2 $6.15M, Q3 $5.72M, Q4 $6.57M); that total already includes about $1.68 million paid to outside lobbying firms.
•AHA's 2026 in-house lobbying fell sharply during the CEO transition: $6.08 million in Q1, $4.47 million in Q2 and $3.84 million in Q3, or $14.39 million year to date, plus about $1.07 million to outside firms.
•AHAPAC reported $3.49 million in receipts for the 2025-2026 cycle through Oct. 14, 2026, with $2.30 million in contributions to other committees, $1.26 million in independent expenditures, and cash on hand down to $683,005.
•At a March 2026 House Energy & Commerce hearing, AHA CEO Pollack was the only one of six panelists to defend the ban on new physician-owned hospitals; no public statement by DeRienzo on that ban or on site-neutral payment has been found.
•His public portfolio centers on clinical leadership, quality, physician well-being and AI, giving AHA a physician face while its lobbyists fight physician-owned competition.

Revolving Door

•Moves between hospital executive suites, AHA, and companies that sell to hospitals, including Mednition, which AHA's own innovation fund backs.
•Concord Health Partners, where he is listed as an adviser, manages the AHA Innovation Development Fund that invested in Mednition, the company on whose board he sits.
•No federal government service is publicly reported.

Home System Record

•As HRET president he heads AHA's research affiliate, which produces studies AHA cites in its advocacy.
•AHA's 2024 Form 990 reports a $22.6 million operating deficit in a year his total pay rose to about $1.06 million.
•AHA, via its innovation fund, holds investments in hospital vendors such as Mednition, mixing trade-association advocacy with venture returns from selling to members.

Litigation and Scrutiny

•No personal litigation, malpractice action or enforcement matter involving DeRienzo has been publicly reported.
•AHA's institutional litigation in 2025-2026 includes the successful D. Maine challenge to HRSA's 340B rebate pilot (injunction Dec. 29, 2025; pilot abandoned Feb. 5, 2026) and a new Oct. 9, 2026 suit against the revised pilot.

Red Flags

He sits on the board of Mednition, a hospital-facing AI vendor backed by the AHA Innovation Fund, while serving as AHA's top physician executive, and any board compensation is undisclosed.

He is also listed as an adviser to Concord Health Partners, the manager of the same AHA innovation fund, creating a loop between his AHA role, the fund, and its portfolio company.

His title lends physician credibility to an association that defends the physician-owned hospital ban and fights site-neutral payment, yet he has made no public statement on either.

He runs HRET, AHA's research arm, so the physician who validates AHA's positions also controls the research pipeline used to support them.

He has never run an independent practice; his career has been inside hospital systems and the businesses that sell to them.

Pattern Summary

Chris DeRienzo is AHA's physician face and head of its research affiliate, paid about $1.06 million in 2024. He also sits on the board of Mednition, a hospital AI vendor backed by the AHA Innovation Fund, and is listed as an adviser to the fund's manager, Concord Health Partners. He talks about quality and physician well-being while AHA lobbies to keep physician-owned hospitals banned and facility fees intact, and he has stayed silent on both.

Chris DeRienzo, MD

Red Flags

Sources and Citations